Results 71 to 80 of about 26,548 (293)

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Duchenne muscular dystrophy incurs nearly universal dilated cardiomyopathy by the third decade of life, preceded by myocardial damage and impaired left ventricular strain by cardiac magnetic resonance.
Subha V. Raman, Kan N. Hor, Wojciech Mazur, Andrea Cardona, Xin He, Nancy Halnon, Larry Markham, Jonathan H. Soslow, Michael D. Puchalski, Scott R. Auerbach, Uyen Truong, Suzanne Smart, Beth McCarthy, Ibrahim M. Saeed, Jeffrey M. Statland, John T. Kissel, Linda H. Cripe   +16 more
doaj   +1 more source

ACTH Antagonists. [PDF]

, 2016
Adrenocorticotropin (ACTH) acts via a highly selective receptor that is a member of the melanocortin receptor subfamily of type 1 G protein-coupled receptors.
Attard, Beardwell, Biller, Boscaro, Bouw, Capatina, Chretien, Chung, Clark, Clark, Colao, Cooray, Cooray, Dores, Draper, Eberle, Fani, Feldhaus, Fridmanis, Goverde, Halem, Han, Hofmann, Hofmann, Joint LWPES/ESPE CAH Working Group, Juszczak, Keller-Wood, Kola, Kovalitskaia, Li, Liang, Lim, Lorimer, Lowry, Malik, Metherell, Miller, Mountjoy, Nensey, Nimkarn, Noon, Osborne, Peri, Pogozheva, Ramachandrappa, Ryan, Samuels, Schwyzer, Schwyzer, Schwyzer, Schöneshöfer, Sebag, Seelig, Seelig, Seferovic, Siepler, Singh, Sonino, Szalay, Veo, Verhelst, Webb, Yang, Zhu   +63 more
core   +3 more sources

Mineralocorticoid receptor antagonists in dialysis patients [PDF]

Renal Replacement Therapy, 2016
Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized.
Tawada, Mitsuhiro, Suzuki, Yasuhiro, Sakata, Fumiko, Mizuno, Masashi, Ito, Yasuhiko   +4 more
openaire   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics

Molecules
The mineralocorticoid receptor (MR) is a steroid hormone receptor that plays a key role in regulating sodium and water homeostasis and blood pressure.
Julia J. Liang, Sara Cao, Andrew Hung, Assam El-Osta, Tom C. Karagiannis, Morag J. Young   +5 more
doaj   +1 more source

Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1‐7)/MAS receptor axes in human mesangial cells

Physiological Reports, 2019
The kidney is an important target of the renin‐ANG‐aldosterone system (RAAS). To date, several studies have demonstrated the existence of a local RAAS in various tissues, including the renal tissue.
Danielle Stoll, Rodrigo Yokota, Danielle Sanches Aragão, Dulce E. Casarini   +3 more
doaj   +1 more source

Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. [PDF]

, 2016
PURPOSE: To evaluate the efficacy and safety of oral mineralocorticoid-receptor antagonist (MRa) therapy in three clinical presentations of nonresolving central serous chorioretinopathy (CSCR) with chronic epitheliopathy.
Behar-Cohen, F., Daruich, A., Dirani, A., Gallice, M., Matet, A., Nicholson, L., Sivaprasad, S.   +6 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. [PDF]

PLoS ONE, 2017
The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease.
Jochen Dutzmann, Robert-Jonathan Musmann, Marco Haertlé, Jan-Marcus Daniel, Kristina Sonnenschein, Andreas Schäfer, Peter Kolkhof, Johann Bauersachs, Daniel G Sedding   +8 more
doaj   +1 more source